drugset
drugset / Trial / NCT01698567

Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)

NCT01698567 ↗

Phase 1 Terminated 6 enrolled University of Rochester
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to discern whether supplementation of Antithrombin III will decrease coagulation and inflammation associated with cardiopulmonary bypass in infants undergoing cardiac surgery.

Timeline

Start
2012-07
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Antithrombin III Protein / enzyme biologic 303 iu —

Indications

congenital heart disease